The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

AIM: To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE‐TIMI 58 trial and surrogate risk factors to predict endpoints not captured within the trial. METHODS: An establishe...

Descripción completa

Detalles Bibliográficos
Autores principales: McEwan, Phil, Morgan, Angharad R., Boyce, Rebecca, Bergenheim, Klas, Gause‐Nilsson, Ingrid A.M., Bhatt, Deepak L., Leiter, Lawrence A., Johansson, Peter A., Mosenzon, Ofri, Cahn, Avivit, Wilding, John P.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048502/
https://www.ncbi.nlm.nih.gov/pubmed/33368855
http://dx.doi.org/10.1111/dom.14308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048502/
https://www.ncbi.nlm.nih.gov/pubmed/33368855
http://dx.doi.org/10.1111/dom.14308

Ejemplares similares